Source: ScreenPro.
  • ScreenPro (SCRN) has welcomed back Andrew Ryu as its interim Chairman and CEO
  • Former CEO and Director, Lena Kozovski, will remain with the company until the end of the year for operational support
  • Ryu brings over 20 years of operational experience with a focus on public and private M&A
  • ScreenPro is a medical technology company offering turnkey screening solutions through its proprietary medical alerting software
  • ScreenPro (SCRN) is unchanged trading at $0.025 per share

ScreenPro (SCRN) has welcomed back Andrew Ryu as its interim Chairman and CEO.

Former CEO and Director, Lena Kozovski, has stepped down from her duties, but will remain with the company until the end of the year as an operational aid.

Former Chairman, Michael Yeung, has also stepped down from the board.

Ryu greatly contributed to ScreenPro’s past success in his previous term as interim Chairman and CEO.

He holds over 20 years of operational experience with a focus on public and private M&A and was nominated as EY Entrepreneur of the Year in 2014.

He previously served as Executive Chairman of Graph Blockchain (GBLC) and Datametrex AI (DM).

“It is with great pleasure that I take on the position as CEO and take the leadership role in operations to help contribute to the company’s success and its value,” stated Ryu. “I believe my wealth of operational and entrepreneurial experience will take the company to new heights and elevate ScreenPro to reach its highest potential.”

ScreenPro is a medical technology company offering turnkey screening solutions through its proprietary medical alerting software.

ScreenPro (SCRN) is unchanged trading at $0.025 per share as of 12:06 pm EST.


More From The Market Online

BlackBerry expands AI-powered cybersecurity service

BlackBerry (TSX:BB) releases the new and expanded CylanceMDR, a managed detection and response tool backed by its Cylance AI platform.

Qualcomm stock jumps on Q2 2024 earnings

Qualcomm (NDAQ:QCOM) shares rise nearly 10 per cent early Thursday on better-than-expected adjusted earnings and strong revenue guidance.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

Fobi AI could address a market in the trillions: Why it’s time to buy

Fobi AI (TSXV:FOBI) is an essential stock to consider to capitalize on the exponential trends of digital wallets and artificial intelligence.